Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Elizabeth Harmon Stover, M.D., Ph.D.

Title
Institution
Department
Address
Phone
Fax

Mentoring
Available: 01/23/23, Expires: 01/01/24

Rare cancers are a significant clinical challenge in the treatment of women with gynecologic malignancies. Many subtypes of gynecologic cancers are considered rare cancers, such as the less common histologies of ovarian, uterine, and cervical cancers, and vaginal and vulvar cancers. Many rare gynecologic cancers have poor outcomes, especially cancers that have recurred after initial treatment. Research and treatment for rare gynecologic cancers have been adversely impacted by limited data and smaller numbers of patients for clinical research, as well as insufficient model systems for laboratory research such as cell lines and animal models. While exciting advances have been made in identifying unique genomic features of certain rare gynecologic tumors, these have not yet translated into new treatments. In the new Rare Gynecologic Cancers Project, we aim to leverage our experience in treating women with rare gynecologic cancers at DFCI to advance research into these malignancies. We aim to compile clinical, pathologic, and genomic data for selected types of rare gynecologic cancers, as well as perform tissue-based analyses and generate patient-derived models. A laboratory component will also investigate therapeutic candidates in cell lines and animal models. Student opportunities for research, depending on student interest and preferences, may include: reviewing and analyzing clinical data from women with rare gynecologic cancers treated at DFCI, reviewing and summarizing the literature on specific cancer types, participating in genomic analysis of targeted sequencing data, coordinating pathology analyses of tissue samples, background research and design of translational studies in cell lines and animal models, and participating in designing and building this new program in rare gynecologic cancers. The laboratory research component could be investigated as an option in the future depending upon student interest, though the current emphasis of the project is on patient-based translational research. Participation in clinical trial design and correlative studies in clinical trials may also be a future component as the project evolves.


Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. K08CA237871 (STOVER, ELIZABETH HARMON) Jul 1, 2019 - Jun 30, 2024
    NIH
    The roles of anti-apoptotic proteins BCL-XL and MCL1 in mediating survival of high-grade serous ovarian cancer following drug-induced DNA damage
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Porter RL, Sun S, Flores MN, Berzolla E, You E, Phillips IE, Kc N, Desai N, Tai EC, Szabolcs A, Lang ER, Pankaj A, Raabe MJ, Thapar V, Xu KH, Nieman LT, Rabe DC, Kolin DL, Stover EH, Pepin D, Stott SL, Deshpande V, Liu JF, Solovyov A, Matulonis UA, Greenbaum BD, Ting DT. Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype. J Clin Invest. 2022 08 15; 132(16). PMID: 35708912; PMCID: PMC9374379.
    Citations:    Fields:    
  2. Liu M, Tayob N, Penter L, Sellars M, Tarren A, Chea V, Carulli I, Huang T, Li S, Cheng SC, Le P, Frackiewicz L, Fasse J, Qi C, Liu JF, Stover EH, Curtis J, Livak KJ, Neuberg D, Zhang G, Matulonis UA, Wu CJ, Keskin DB, Konstantinopoulos PA. Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer. Clin Cancer Res. 2022 08 02; 28(15):3356-3366. PMID: 35443043; PMCID: PMC9357177.
    Citations:    Fields:    
  3. Stover EH, Xiong N, Myers AP, Tayob N, Engvold V, Polak M, Broaddus RR, Makker V, Drapkin R, Liu JF, Horowitz NS, Meric-Bernstam F, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN, Konstantinopoulos PA. A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecol Oncol Rep. 2022 Apr; 40:100974. PMID: 35434236; PMCID: PMC9011027.
    Citations:    
  4. Stover EH, Oh C, Keskula P, Choudhury AD, Tseng YY, Adalsteinsson VA, Lohr JG, Thorner AR, Ducar M, Kryukov GV, Ha G, Rosenberg M, Freeman SS, Zhang Z, Wu X, Van Allen EM, Takeda DY, Loda M, Wu CL, Taplin ME, Garraway LA, Boehm JS, Huang FW. Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. Prostate. 2022 04; 82(5):584-597. PMID: 35084050; PMCID: PMC8887817.
    Citations:    Fields:    Translation:HumansCells
  5. Dominas C, Bhagavatula S, Stover E, Deans K, Larocca C, Colson Y, Peruzzi P, Kibel A, Hata N, Tsai L, Hung Y, Packard R, Jonas O. The Translational and Regulatory Development of an Implantable Microdevice for Multiple Drug Sensitivity Measurements in Cancer Patients. IEEE Trans Biomed Eng. 2022 01; 69(1):412-421. PMID: 34242160; PMCID: PMC8702455.
    Citations: 1     Fields:    Translation:HumansAnimals
  6. Konstantinopoulos PA, da Costa AABA, Gulhan D, Lee EK, Cheng SC, Hendrickson AEW, Kochupurakkal B, Kolin DL, Kohn EC, Liu JF, Stover EH, Curtis J, Tayob N, Polak M, Chowdhury D, Matulonis UA, Färkkilä A, D'Andrea AD, Shapiro GI. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun. 2021 09 22; 12(1):5574. PMID: 34552099; PMCID: PMC8458434.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  7. Weber ZT, Collier KA, Tallman D, Forman J, Shukla S, Asad S, Rhoades J, Freeman S, Parsons HA, Williams NO, Barroso-Sousa R, Stover EH, Mahdi H, Cibulskis C, Lennon NJ, Ha G, Adalsteinsson VA, Tolaney SM, Stover DG. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. Genome Med. 2021 05 20; 13(1):89. PMID: 34016182; PMCID: PMC8136103.
    Citations: 4     Fields:    Translation:Humans
  8. Richter C, Mayhew D, Rennhack JP, So J, Stover EH, Hwang JH, Szczesna-Cordary D. Genomic Amplification and Functional Dependency of the Gamma Actin Gene ACTG1 in Uterine Cancer. Int J Mol Sci. 2020 Nov 18; 21(22). PMID: 33217970.
    Citations: 8     Fields:    Translation:HumansCells
  9. Albayrak A, Garrido-Castro AC, Giannakis M, Umeton R, Manam MD, Stover EH, Porter RL, Johnson BE, Liaw KL, Amonkar M, Church AJ, Janeway KA, Nowak JA, Sholl L, Lin NU, Johnson JM. Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing. JCO Precis Oncol. 2020 Nov; 4:1084-1097. PMID: 35050773.
    Citations: 1     Fields:    
  10. Stover EH, Fuh K, Konstantinopoulos PA, Matulonis UA, Liu JF. Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol. 2020 12; 159(3):887-898. PMID: 33012552.
    Citations: 19     Fields:    Translation:HumansCells
  11. Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, Khabele D, Mosammaparast N, Vindigni A. Homologous recombination deficiency real-time clinical assays, ready or not? Gynecol Oncol. 2020 12; 159(3):877-886. PMID: 32967790.
    Citations: 12     Fields:    Translation:HumansCells
  12. Lee EK, Xiong N, Cheng SC, Barry WT, Penson RT, Konstantinopoulos PA, Hoffman MA, Horowitz N, Dizon DS, Stover EH, Wright AA, Campos SM, Krasner C, Morrissey S, Whalen C, Quinn R, Matulonis UA, Liu JF. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78. PMID: 32771276.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  13. Slyper M, Porter CBM, Ashenberg O, Waldman J, Drokhlyansky E, Wakiro I, Smillie C, Smith-Rosario G, Wu J, Dionne D, Vigneau S, Jané-Valbuena J, Tickle TL, Napolitano S, Su MJ, Patel AG, Karlstrom A, Gritsch S, Nomura M, Waghray A, Gohil SH, Tsankov AM, Jerby-Arnon L, Cohen O, Klughammer J, Rosen Y, Gould J, Nguyen L, Hofree M, Tramontozzi PJ, Li B, Wu CJ, Izar B, Haq R, Hodi FS, Yoon CH, Hata AN, Baker SJ, Suvà ML, Bueno R, Stover EH, Clay MR, Dyer MA, Collins NB, Matulonis UA, Wagle N, Johnson BE, Rotem A, Rozenblatt-Rosen O, Regev A. Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 Aug; 26(8):1307. PMID: 32587393.
    Citations: 2     Fields:    
  14. Izar B, Tirosh I, Stover EH, Wakiro I, Cuoco MS, Alter I, Rodman C, Leeson R, Su MJ, Shah P, Iwanicki M, Walker SR, Kanodia A, Melms JC, Mei S, Lin JR, Porter CBM, Slyper M, Waldman J, Jerby-Arnon L, Ashenberg O, Brinker TJ, Mills C, Rogava M, Vigneau S, Sorger PK, Garraway LA, Konstantinopoulos PA, Liu JF, Matulonis U, Johnson BE, Rozenblatt-Rosen O, Rotem A, Regev A. A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020 08; 26(8):1271-1279. PMID: 32572264.
    Citations: 77     Fields:    Translation:HumansCells
  15. Slyper M, Porter CBM, Ashenberg O, Waldman J, Drokhlyansky E, Wakiro I, Smillie C, Smith-Rosario G, Wu J, Dionne D, Vigneau S, Jané-Valbuena J, Tickle TL, Napolitano S, Su MJ, Patel AG, Karlstrom A, Gritsch S, Nomura M, Waghray A, Gohil SH, Tsankov AM, Jerby-Arnon L, Cohen O, Klughammer J, Rosen Y, Gould J, Nguyen L, Hofree M, Tramontozzi PJ, Li B, Wu CJ, Izar B, Haq R, Hodi FS, Yoon CH, Hata AN, Baker SJ, Suvà ML, Bueno R, Stover EH, Clay MR, Dyer MA, Collins NB, Matulonis UA, Wagle N, Johnson BE, Rotem A, Rozenblatt-Rosen O, Regev A. A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 05; 26(5):792-802. PMID: 32405060; PMCID: PMC7220853.
    Citations: 85     Fields:    Translation:HumansAnimalsCells
  16. Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, Bhola PD, Ryan J, Guerriero JL, Montero J, Liang FJ, Cherniack AD, Piccioni F, Matulonis UA, Bowtell DDL, Sarosiek KA, Letai A, Garraway LA, Johannessen CM, Meyerson M. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Mol Cancer Res. 2019 11; 17(11):2281-2293. PMID: 31462500.
    Citations: 10     Fields:    Translation:HumansCells
  17. Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794. PMID: 31461377; PMCID: PMC9798913.
    Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
  18. Ditzel HM, Strickland KC, Meserve EE, Stover E, Konstantinopoulos PA, Matulonis UA, Muto MG, Liu JF, Feltmate C, Horowitz N, Berkowitz RS, Gupta M, Hecht JL, Lin DI, Jochumsen KM, Welch WR, Hirsch MS, Quade BJ, Lee KR, Crum CP, Mutter GL, Nucci MR, Howitt BE. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2019 May; 38(3):230-240. PMID: 29750700.
    Citations: 7     Fields:    Translation:Humans
  19. Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018 12 11; 25(11):2972-2980.e5. PMID: 30540933.
    Citations: 149     Fields:    Translation:HumansAnimalsCells
  20. Stover EH, Feltmate C, Berkowitz RS, Lindeman NI, Matulonis UA, Konstantinopoulos PA. Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma. JCO Precis Oncol. 2018; 2018. PMID: 30828692; PMCID: PMC6394870.
    Citations: 2     Fields:    
  21. Ghazani AA, Oliver NM, St Pierre JP, Garofalo A, Rainville IR, Hiller E, Treacy DJ, Rojas-Rudilla V, Wood S, Bair E, Parello M, Huang F, Giannakis M, Wilson FH, Stover EH, Corsello SM, Nguyen T, Rana HQ, Church AJ, Lowenstein C, Cibulskis C, Amin-Mansour A, Heng J, Brais L, Santos A, Bauer P, Waldron A, Lo P, Gorman M, Lydon CA, Welch M, McNamara P, Gabriel S, Sholl LM, Lindeman NI, Garber JE, Joffe S, Van Allen EM, Gray SW, Ja Nne PA, Garraway LA, Wagle N. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genet Med. 2017 07; 19(7):787-795. PMID: 28125075.
    Citations: 21     Fields:    Translation:Humans
  22. Stover EH, Konstantinopoulos PA, Matulonis UA, Swisher EM. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. Clin Cancer Res. 2016 Dec 01; 22(23):5651-5660. PMID: 27678458.
    Citations: 59     Fields:    Translation:HumansCells
  23. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, Matulonis UA, Konstantinopoulos PA. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015 Dec; 1(9):1319-23. PMID: 26181000.
    Citations: 227     Fields:    Translation:HumansCells
  24. Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, Armstrong SA, Ghilardi N, Gould S, de Sauvage FJ, McMahon AP, Gilliland DG. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell. 2009 Jun 05; 4(6):559-67. PMID: 19497284.
    Citations: 82     Fields:    Translation:AnimalsCells
  25. Schwarzberg AB, Stover EH, Sengupta T, Michelini A, Vincitore M, Baden LR, Kulke MH. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest. 2007 Jun; 25(4):249-55. PMID: 17612935.
    Citations: 16     Fields:    Translation:Humans
  26. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, Williams IR, Gilliland DG, Cools J. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci U S A. 2006 May 23; 103(21):8078-83. PMID: 16690743.
    Citations: 39     Fields:    Translation:HumansAnimalsCells
  27. Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W, Boogaerts M, Vandenberghe P, Marynen P, Cools J. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood. 2006 Aug 15; 108(4):1374-6. PMID: 16645167; PMCID: PMC1895882.
    Citations: 30     Fields:    Translation:HumansCells
  28. Cools J, Stover EH, Gilliland DG. Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia. Methods Mol Med. 2006; 125:177-87. PMID: 16502585.
    Citations: 5     Fields:    Translation:HumansCells
  29. Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J, Cullen D, Coburn A, Moore SA, Okabe R, Fabbro D, Manley PW, Griffin JD, Gilliland DG. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood. 2005 Nov 01; 106(9):3206-13. PMID: 16030188; PMCID: PMC1895333.
    Citations: 32     Fields:    Translation:HumansAnimalsCells
  30. Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol. 2004 Jan; 11(1):51-7. PMID: 14676627.
    Citations: 19     Fields:    Translation:HumansCells
  31. Gilliland G, Cools J, Stover EH, Wlodarska I, Marynen P. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis. Hematol J. 2004; 5 Suppl 3:S133-7. PMID: 15190295.
    Citations: 3     Fields:    Translation:HumansAnimals
  32. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams IR, Coutre SE, Stone RM, DeAngelo DJ, Marynen P, Manley PW, Meyer T, Fabbro D, Neuberg D, Weisberg E, Griffin JD, Gilliland DG. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRa-induced myeloproliferative disease. Cancer Cell. 2003 May; 3(5):459-69. PMID: 12781364.
    Citations: 50     Fields:    Translation:HumansAnimalsCells
  33. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27; 348(13):1201-14. PMID: 12660384.
    Citations: 380     Fields:    Translation:HumansCells
  34. Merighi M, Majerczak DR, Stover EH, Coplin DL. The HrpX/HrpY two-component system activates hrpS expression, the first step in the regulatory cascade controlling the Hrp regulon in Pantoea stewartii subsp. stewartii. Mol Plant Microbe Interact. 2003 Mar; 16(3):238-48. PMID: 12650455.
    Citations: 28     Fields:    Translation:Cells
  35. Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, You MJ, Tang Y, DeFrances J, Stover E, Weissleder R, Rowitch DH, Louis DN, DePinho RA. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell. 2002 Apr; 1(3):269-77. PMID: 12086863.
    Citations: 276     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Stover's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (224)
Explore
_
Co-Authors (111)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.